SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced that its Decipher ® Prostate RP genomic classifier is uniquely recommended in the 2022 National ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced that new data from a large, randomized phase 3 trial reinforce the value of the Decipher Prostate Genomic ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc (VCYT). (Nasdaq: VCYT), a leading cancer diagnostics company, announced that new data from the multicenter, prospective VANDAAM trial show ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its Decipher Prostate Genomic Classifier is the only gene ...
Findings are from the multicenter, prospective, Phase 3 STAMPEDE trial “Our findings suggest that the Decipher Prostate test may provide an important new tool to help guide treatment decisions for the ...
A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease to come back quickly after ...
GenomeDx Biosciences today announced that data presented at the 2015 American Society of Clinical Oncology Annual Meeting demonstrate that the Decipher® Prostate Cancer Classifier is a significant ...
A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at ...
Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, and University College London (UCL) today announced that data published online in Cell show that the Decipher Prostate Genomic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback